stilbenes and Clostridium-Infections

stilbenes has been researched along with Clostridium-Infections* in 3 studies

Other Studies

3 other study(ies) available for stilbenes and Clostridium-Infections

ArticleYear
A 14-day repeat dose oral gavage range-finding study of a first-in-class CDI investigational antibiotic, in rats.
    Scientific reports, 2019, 01-17, Volume: 9, Issue:1

    Drug resistant bacteria are winning the fight over antibiotics with some bacteria not responding to any antibiotics, threatening modern medicine as we know it. The development of new, effective and safe antibiotics is critical for addressing this issue. Ramizol, a first-in-class styrylbenzene based antibiotic, is an investigational drug indicated for Clostridium difficile infections (CDI). The objective of this range-finding study was to evaluate the potential general toxicity (based on toxicological endpoints selected) and toxicokinetics of Ramizol in male and female rats that may arise from repeated exposure via oral gavage over a test period of at least 14 days at doses of 50 mg/kg, 500 mg/kg and 1500 mg/kg. There were no mortalities in this study and no Ramizol-related clinical observations. Additionally, there were no changes in mean body weight, body weight gain, food consumption or food efficiency for male and female rats attributable to Ramizol administration. The observed pharmacokinetic behavior showed the presence of Ramizol in plasma at 24 hours post-dosing combined with increasing AUC(0-24) values during the course of this study in groups administered 1500 mg/kg/day, which suggests that at least some dosing groups will show accumulation of compound during repeated dose studies. These toxicology results have shown Ramizol is well-tolerated at very high concentrations in rats and support the further drug development of Ramizol as a first-in-class antibiotic for the treatment of CDI.

    Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Benzoates; Body Weight; Clostridium Infections; Dose-Response Relationship, Drug; Female; Male; Rats; Rats, Sprague-Dawley; Stilbenes

2019
Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis.
    The Journal of antibiotics, 2016, Volume: 69, Issue:12

    Antibiotic-resistant bacteria is a major threat to human health and is predicted to become the leading cause of death from disease by 2050. Despite the recent resurgence of research and development in the area, few antibiotics have reached the market, with most of the recently approved antibiotics corresponding to new uses for old antibiotics, or structurally similar derivatives thereof. We have recently reported an in silico approach that led to the design of an entirely new class of antibiotics for the bacteria-specific mechanosensitive ion channel of large conductance: MscL. Here, we present the preclinical development of one such antibiotic, Ramizol, a first generation antibiotic belonging to that class. We present the lack of interaction between Ramizol and other mammalian channels adding credibility to its MscL selectivity. We determine the pharmacokinetic profile in a rat model and show <0.1% of Ramizol is absorbed systemically. We show this non-systemic nature of the antibiotic translates to over 70% survival of hamsters in a Clostridium difficile colitis model. Lastly, initial in vitro data indicate that resistance to Ramizol occurs at a low frequency. In conclusion, we establish the potential of Ramizol as an effective new treatment for C. difficile associated disease.

    Topics: Animals; Anti-Bacterial Agents; Benzoates; Clostridioides difficile; Clostridium Infections; Colitis; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Male; Mesocricetus; Microbial Sensitivity Tests; Rats; Rats, Sprague-Dawley; Stilbenes

2016
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas.
    FEMS immunology and medical microbiology, 2001, Volume: 30, Issue:1

    Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm(2) and 3 cm(2). Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host.

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Clostridium; Clostridium Infections; Colony Count, Microbial; Disease Models, Animal; Genetic Therapy; Genetic Vectors; Humans; Metronidazole; Rats; Rhabdomyosarcoma; Spores, Bacterial; Stilbenes

2001